MVC COVID-19 vaccine
COVID-19 vaccine made by Medigen
The MVC COVID-19 vaccine (Chinese: 高端新冠肺炎疫苗; pinyin: Gāoduān xīnguàn fèiyán yìmiáo; Wade–Giles: Kaotuan hsinkuan feiyen imiao), designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.
Technology
This vaccine is made by the recombinant S-2P spike protein. It is adjuvanted with CpG 1018 supplied by Dynavax, which was used in a previously FDA-approved adult hepatitis B vaccine.
Clinical trials
On 16 February 2020, Medigen Vaccine Biologics Corporation (MVC) signed a collaboration agreement with US National Institutes of Health (NIH) for COVID-19 vaccine development. The partnership will allow MVC to obtain NIH's COVID-19 vaccine and related biological materials to conduct animal studies in Taiwan. On 23 July 2020, Medigen announced collaboration with Dynavax Technologies to develop COVID-19 vaccine.
On 13 October 2020, MVC received Taiwan's government subsidies for the initiation of Phase 1 Clinical Trial in Taiwan starting early October. The Phase 1 Clinical Trial was held at National Taiwan University Hospital with 45 participants ranging the age of 20–50.
On 25 January 2021, MVC initiated a Phase 2 Clinical Trial for its COVID-19 vaccine candidate MVC-COV1901 with the first participant being dosed. The multi-center, randomized, placebo-controlled trial included 3,844 participants aged 20 or older.
Begin with the source’s own compact description: “MVC COVID-19 vaccine” is cOVID-19 vaccine made by Medigen. The dossier treats that line as a proposition to test through COVID-19, vaccine and made, not as a finished interpretation.
Why this record matters
The phrase “cOVID-19 vaccine made by Medigen” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 10, 2026. The linked authority identifier is Q101251575. The first chronological checks are 1018, 2020 and 2021.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “MVC COVID-19 vaccine”, its source revision and the description used here.
- Expand the search: follow MVC COVID-19 vaccine primary sources, MVC COVID-19 vaccine archive and COVID-19 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “MVC COVID-19 vaccine”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “MVC COVID-19 vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.